866-997-4948(US-Canada Toll Free)

Bioinformatics Partnering Terms and Agreements

Published By :

Current Partnering

Published Date : Sep 2013

Category :

Biotechnology

No. of Pages : 1268 Pages


The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe bioinformatics partnering deals and agreements entered intby the worlds leading healthcare companies.

  • Trends in bioinformatics partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe bioinformatics partnering deals and agreements entered intby the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right tlicense the licensors bioinformatics technology. These deals tend tbe multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

Bioinformatics is the application of computer science and information technology tthe field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order tspeed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intthe negotiation process in terms of what you can expect tachieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases dnot.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2007, including financial terms where available, including over 1700 links tonline deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted tthe Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. 

Chapter 1 provides an introduction tthe report, whilst 

Chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access tthe contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink tan online version of the actual contract document, providing easy access teach contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink tan online version of the actual contract document, providing easy access teach contract document on demand.

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink tan online version of the deal record and where available, the contract document, providing easy access teach contract document on demand.

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z , deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink tan online version of the deal record and where available, the contract document, providing easy access teach contract document on demand.

The report alsincludes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs tknow about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2007
  • Access theadline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access tover 1700  bioinformatics deals entered intby the world’s biopharma companies
  • Detailed access tactual bioinformatics contracts enter intby the leading fifty bigpharma companies
  • Insight intthe terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence tassess suitability of your proposed deal terms for partner companies

Report scope

Bioinformatics Partnering Terms and Agreements is intended tprovide the reader with an in-depth understanding and access tbioinformatics trends and structure of deals entered intby leading companies worldwide.

Bioinformatics Partnering Terms and Agreements includes:

  • Trends in bioinformatics dealmaking in the biopharma industry since 2007
  • Analysis of bioinformatics deal structure
  • Access theadline, upfront, milestone and royalty data
  • Case studies of real-life bioinformatics deals
  • Access tover 1700 bioinformatics deal documents
  • Access tcontract documents where available
  • The leading bioinformatics deals by value since 2007
  • Most active bioinformatics dealmakers since 2007

The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target

Each deal title links via Weblink tan online version of the deal record and where available, the contract document, providing easy access teach contract document on demand. The Bioinformatics Partnering Terms and Agreements report provides comprehensive access tavailable deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise bioinformatics rights granted or optioned?
  • What is actually granted by the agreement tthe partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Whis responsible for commercialization?
  • Whis responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed? How are disputes tbe resolved?
  • Under what conditions can the deal be terminated? What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear tdiffer from partner tpartner or deal type tdeal type?
  • Which jurisdiction does the company insist upon for agreement law?

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2007
  • Access theadline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access tover 1700 bioinformatics deal documents entered intby the world’s biopharma companies
  • Detailed access tactual bioinformatics contracts 
  • Provides insight intdeals dentered by top 50 big pharma and top big biotech companies
  • Insight intthe terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence tassess suitability of your proposed deal terms for partner companies
TABLE OF CONTENT

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in bioinformatics dealmaking
2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Big pharma bioinformatics dealmaking activity
2.4. Big Biotech bioinformatics dealmaking activity
2.5. Most active bioinformatics dealmakers
2.6. Bioinformatics partnering by deal type
2.7. Bioinformatics partnering by stage of development
2.8. Bioinformatics partnering by disease type
2.9. Average deal terms for bioinformatics partnering
2.9.1 Bioinformatics partnering headline values
2.9.2 Bioinformatics deal upfront payments
2.9.3 Bioinformatics deal milestone payments
2.9.4 Bioinformatics royalty rates

Chapter 3 – Leading bioinformatics deals
3.1. Introduction
3.2. Top bioinformatics deals by value
3.3. Top bioinformatics deals involving big pharma

Chapter 4 – Bigpharma bioinformatics deals
4.1. Introduction
4.2. How to use bigpharma bioinformatics partnering deals
4.3. Big pharma bioinformatics partnering company profiles
Abbott
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Galderma
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Valeant

Chapter 5 – Bigbiotech bioinformatics deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech bioinformatics partnering company profiles
Array Biopharma
Dendreon
Elan
Galapagos
Genmab
Grifols
Ipsen
Novo Nordisk
Onyx Pharmaceuticals
Spectrum Pharmaceuticals
Vertex Pharmaceuticals

Chapter 6 – Bioinformatics dealmaking directory with contracts
6.1. Introduction
6.2. By stage of development
Discovery
Formulation
Marketed
Phase III
6.3. By deal type
Asset purchase
Bigpharma outlicensing
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Licensing
Litigation
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
6.4. By therapy area
Cardiovascular
Hematology
Hospital care
Infectives
Oncology

Chapter 7 – Bioinformatics dealmaking by technology type
Bioinformatics
Software tools

Chapter 8 – Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports

Appendices

Appendix 1: By company A-Z

Appendix 2: By stage of development

Appendix 3: By deal type

Appendix 4: By therapy area

List of Chart


Figure 1: Bioinformatics partnering since 2007
Figure 2: Big pharma – top 50 – bioinformatics deals 2007 to 2013
Figure 3: Big pharma biomarker deal frequency – 2007 to 2013
Figure 4: Big biotech – top 50 – bioinformatics deals 2007 to 2013
Figure 5: Big biotech biomarker deal frequency – 2007 to 2013
Figure 6: Active bioinformatics dealmaking activity– 2007 to 2013
Figure 4: Bioinformatics partnering by deal type since 2007
Figure 5: Bioinformatics partnering by deal type since 2007
Figure 6: Bioinformatics partnering by disease type since 2007
Figure 10: Bioinformatics deals with a headline value – by stage of development
Figure 11: Bioinformatics deal headline value distribution – discovery stage, US$million
Figure 12: Bioinformatics deal headline value distribution – preclinical stage, US$million
Figure 13: Bioinformatics deal headline value distribution – phase I stage, US$million
Figure 14: Bioinformatics deal headline value distribution – phase II stage, US$million
Figure 15: Bioinformatics deal headline value distribution – phase III stage, US$million
Figure 16: Bioinformatics deal headline value distribution – regulatory stage, US$million
Figure 17: Bioinformatics deal headline value distribution – marketed stage, US$million
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19: Bioinformatics deals with upfront payment values – by stage of development
Figure 20: Bioinformatics deal upfront payment distribution – discovery stage, US$million
Figure 21: Bioinformatics deal upfront payment distribution – preclinical stage, US$million
Figure 22: Bioinformatics deal upfront payment distribution – phase I stage, US$million
Figure 23: Bioinformatics deal upfront payment distribution – phase II stage, US$million
Figure 24: Bioinformatics deal upfront payment distribution – phase III stage, US$million
Figure 25: Bioinformatics deal upfront payment distribution – regulatory stage, US$million
Figure 26: Bioinformatics deal upfront payment distribution – phase marketed stage, US$million
Figure 27: Summary median upfront value by stage of development, 2007-2013
Figure 28: Bioinformatics deals with milestone payments – by stage of development
Figure 29: Bioinformatics deal milestone value distribution, US$million – discovery stage
Figure 30: Bioinformatics deal milestone value distribution, US$million – preclinical stage
Figure 31: Bioinformatics deal milestone value distribution, US$million – phase I stage
Figure 32: Bioinformatics deal milestone value distribution, US$million – phase II stage
Figure 33: Bioinformatics deal milestone value distribution, US$million – phase III stage
Figure 34: Bioinformatics deal milestone value distribution, US$million – regulatory stage
Figure 35: Bioinformatics deal milestone value distribution, US$million – marketed stage
Figure 36: Bioinformatics deals with royalty rates- by stage of development
Figure 37: Bioinformatics deal royalty rates value distribution, US$million – discovery stage
Figure 38: Bioinformatics deal royalty rates value distribution, US$million – preclinical stage
Figure 39: Bioinformatics deal royalty rates value distribution, US$million – phase I stage
Figure 40: Bioinformatics deal royalty rates value distribution, US$million – phase II stage
Figure 41: Bioinformatics deal royalty rates value distribution, US$million – phase III stage
Figure 42: Bioinformatics deal royalty rates value distribution, US$million – regulatory stage
Figure 43: Bioinformatics deal royalty rates value distribution, US$million – marketed stage
Figure 44: Summary median milestone value by stage of development, 2007-2013
Figure 45: Top bioinformatics deals by value since 2007
Figure 46: Top bioinformatics deals signed by big pharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *